Online & In-The-Know: Shingles and Vaccination

This presentation will discuss herpes zoster and its complications. We will discuss the current approved vaccine (RZV) for the prevention of Shingles, patient expectations and strategies for second dose completion. The presenter will also discuss immunization rates among the current population and what the impact of lowering the age recommendation from 60 to 50 regarding numbers of patients eligible in the general population

Presented by: Ron Smolen Pharm.D, Medical Science Liaison, Vaccines, Medical Affairs